|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 6318 |
FusionGeneSummary for CDC20_PIP4K2B |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CDC20_PIP4K2B | Fusion gene ID: 6318 | Hgene | Tgene | Gene symbol | CDC20 | PIP4K2B | Gene ID | 991 | 8396 |
| Gene name | cell division cycle 20 | phosphatidylinositol-5-phosphate 4-kinase type 2 beta | |
| Synonyms | CDC20A|bA276H19.3|p55CDC | PI5P4KB|PIP5K2B|PIP5KIIB|PIP5KIIbeta|PIP5P4KB | |
| Cytomap | 1p34.2 | 17q12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cell division cycle protein 20 homologCDC20 cell division cycle 20 homologcell division cycle 20 homolog | phosphatidylinositol 5-phosphate 4-kinase type-2 beta1-phosphatidylinositol 5-phosphate 4-kinase 2-beta1-phosphatidylinositol-4-phosphate kinasePI(5)P 4-kinase type II betaPIP4KII-betaPTDINS(4)P-5-kinasediphosphoinositide kinase 2-betaphosphatidyli | |
| Modification date | 20180522 | 20180519 | |
| UniProtAcc | Q12834 | P78356 | |
| Ensembl transtripts involved in fusion gene | ENST00000310955, ENST00000372462, ENST00000478882, | ENST00000269554, ENST00000311500, | |
| Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 7 X 6 X 4=168 |
| # samples | 3 | 9 | |
| ** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(9/168*10)=-0.900464326449086 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CDC20 [Title/Abstract] AND PIP4K2B [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CDC20 | GO:0031145 | anaphase-promoting complex-dependent catabolic process | 17443180 |
| Hgene | CDC20 | GO:1904668 | positive regulation of ubiquitin protein ligase activity | 11459826 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BP428483 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-3UTR | ENST00000310955 | ENST00000269554 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| 5CDS-intron | ENST00000310955 | ENST00000311500 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| 5CDS-3UTR | ENST00000372462 | ENST00000269554 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| 5CDS-intron | ENST00000372462 | ENST00000311500 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| intron-3UTR | ENST00000478882 | ENST00000269554 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
| intron-intron | ENST00000478882 | ENST00000311500 | CDC20 | chr1 | 43828782 | + | PIP4K2B | chr17 | 36922526 | - |
Top |
FusionProtFeatures for CDC20_PIP4K2B |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CDC20 | PIP4K2B |
| Required for full ubiquitin ligase activity of theanaphase promoting complex/cyclosome (APC/C) and may confersubstrate specificity upon the complex. Is regulated by MAD2L1: inmetaphase the MAD2L1-CDC20-APC/C ternary complex is inactive andin anaphase the CDC20-APC/C binary complex is active in degradingsubstrates. The CDC20-APC/C complex positively regulates theformation of synaptic vesicle clustering at active zone to thepresynaptic membrane in postmitotic neurons. CDC20-APC/C-induceddegradation of NEUROD2 induces presynaptic differentiation.{ECO:0000269|PubMed:9637688, ECO:0000269|PubMed:9734353,ECO:0000269|PubMed:9811605}. | Participates in the biosynthesis of phosphatidylinositol4,5-bisphosphate. {ECO:0000269|PubMed:9038203}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CDC20_PIP4K2B |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for CDC20_PIP4K2B |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CDC20_PIP4K2B |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for CDC20_PIP4K2B |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|